Equities
Health CareMedical Equipment and Services
  • Price (HKD)1.71
  • Today's Change-0.01 / -0.58%
  • Shares traded606.00k
  • 1 Year change+18.75%
  • Beta0.8641
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

LifeTech Scientific Corp is an investment holding company primarily engaged in the development, manufacture and trading of interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The Company mainly operates its business through three segments. The Structural Heart Diseases Business segment is engaged in trading, manufacture, research and development of devices related to structural heart diseases. The Peripheral Vascular Diseases Business segment is engaged in trading, manufacture, research and development of devices related to peripheral vascular diseases. The Cardiac Pacing and Electrophysiology Business segment is engaged in trading, manufacture, research and development of devices related to cardiac pacing and electrophysiology. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)1.50bn
  • Net income in HKD81.35m
  • Incorporated2006
  • Employees1.27k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Peijia Medical Ltd755.33m-254.75m4.12bn1.04k--1.84--5.45-0.3851-0.38511.143.330.25611.4017.04721,424.50-8.76-26.57-10.02-28.9969.2571.23-34.21-247.651.49-15.300.1396--39.53101.1342.28--83.33--
Acotec Scientific Holdings Ltd670.70m114.15m4.32bn645.0036.802.6424.846.440.37440.37442.235.210.33531.063.531,031,848.005.710.24676.450.28975.2381.3317.020.71225.57--0.14060.0012.6933.72260.8817.7483.44--
MicroPort CardioFlow Medtech Corp415.79m5.49m5.41bn417.00361.220.830650.3113.020.00240.00240.17851.020.14231.001.77966,955.600.0886-13.380.0996-16.8469.0864.410.6228-124.496.50--0.112--7.5475.8589.51--26.60--
Modern Dental Group Ltd3.50bn478.00m5.47bn8.59k11.491.838.761.560.50930.50933.733.190.82979.044.89492,119.5011.428.0813.349.6054.0651.8513.7610.322.7654.800.199940.786.056.990.965120.360.4449--
Lepu Scientch Mdcl Tchnlgy Shnghi Co Ltd624.77m325.09m5.73bn374.0017.632.5716.039.170.93750.93751.806.440.24940.83236.061,989,699.0012.987.8314.899.2887.2389.1852.0335.625.03--0.000681.7844.4032.2862.2236.4582.59--
Yidu Tech Inc841.28m-100.62m6.30bn823.00--1.45--7.48-0.0953-0.09530.79534.120.159524.781.341,022,216.00-2.03-24.00-2.38-30.0834.4135.64-12.72-123.004.37--0.0321---11.415.0839.58--26.45--
Shanghai INT Medical Instruments Co Ltd1.04bn202.40m6.54bn2.01k25.672.5721.156.281.211.216.2212.060.38022.0511.49600,349.607.988.4610.149.8160.9960.3421.0024.360.96626.740.225324.3113.1724.3615.6312.6817.46--
China Isotope & Radiation Corp8.62bn479.84m6.56bn3.36k13.681.145.010.76121.501.5026.9617.970.51863.141.752,561,072.006.226.3112.9912.9948.2655.5411.9911.951.5168.900.27530.1614.1613.689.624.3311.8123.56
BrainAurora Medical Technology Ltd192.86m-237.94m6.61bn174.00--22.03--34.30-0.1879-0.18790.15230.22110.3274--1.241,212,958.00-40.54---112.29--41.26---123.83-----10.130.6324--82.01--44.78------
MicroPort NeuroScientific Corp833.17m230.32m6.86bn522.0029.853.5123.168.230.3990.3991.443.400.35431.293.101,580,970.009.696.0411.237.0173.5874.5827.3616.604.71142.060.014135.6914.4432.9074.6340.172.49--
AK Medical Holdings Ltd1.57bn334.06m6.91bn1.00k20.612.2315.154.420.29840.29841.402.750.4111.062.661,640,641.008.778.0110.899.6959.2763.0121.3420.182.88--0.074722.5723.087.7650.420.51418.660.1873
Zylox-Tonbridge Medical Technolgy Co Ltd1.02bn172.63m7.89bn875.0044.022.1036.827.760.53160.53163.1411.120.25731.40425.711,161,637.004.37-3.214.84-3.4471.4772.7516.98-21.205.16--0.0257--48.27175.65227.34--35.70--
LifeTech Scientific Corp1.50bn81.35m7.92bn1.27k91.391.8667.325.270.01870.01870.34570.92090.26150.69758.111,078,952.000.48166.080.58227.2672.6078.531.8420.722.09--0.13080.002.8814.28-15.5211.4715.11--
Xunfei Healthcare Technology Co Ltd908.82m-87.15m10.53bn928.00--10.56--11.58-0.721-0.7217.528.250.44713.361.11997,604.40-4.80---11.06--54.37---10.73--1.49--0.3613--31.98--8.45------
Data as of Feb 16 2026. Currency figures normalised to LifeTech Scientific Corp's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

12.58%Per cent of shares held by top holders
HolderShares% Held
HHLR Advisors Ltd.as of 26 Sep 2024229.76m4.96%
The Vanguard Group, Inc.as of 04 Feb 2026145.51m3.14%
BlackRock Fund Advisorsas of 06 Feb 202652.92m1.14%
Dimensional Fund Advisors LPas of 05 Feb 202648.50m1.05%
Bosera Asset Management Co., Ltd.as of 30 Jun 202530.26m0.65%
Norges Bank Investment Managementas of 30 Jun 202522.05m0.48%
China Asset Management Co., Ltd.as of 30 Jun 202518.21m0.39%
BlackRock Advisors (UK) Ltd.as of 06 Feb 202615.23m0.33%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202510.44m0.23%
SSgA Funds Management, Inc.as of 05 Feb 20269.80m0.21%
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.